IIP Completes $270M IQHQ Investment as Leasing Momentum Builds
Event summary
- IIP fully funded $270M investment in IQHQ, including $120M in Series G preferred equity during Q2 2026.
- Generated $53M in AFFO (Adjusted Funds from Operations) for Q2 2026, up from $48.4M year-over-year.
- Executed a 58K sq ft lease with Curaleaf and resolved litigation with PharmaCann.
- Completed $402.5M upsized private offering of exchangeable senior notes due 2029.
The big picture
IIP's Q2 results reflect its dual strategy of expanding its portfolio through strategic investments like IQHQ while maintaining financial discipline. The company's ability to navigate tenant defaults and reposition properties will be critical as the cannabis industry faces regulatory uncertainty. With $3B in total gross assets and a net debt-to-EBITDA ratio of 1.7x, IIP appears well-positioned to capitalize on growth opportunities.
What we're watching
- Tenant Transition Risk
- How the pace of securing new tenants for properties previously leased to defaulted operators like PharmaCann and 4Front will impact occupancy rates.
- Capital Deployment Strategy
- Whether IIP can sustain its aggressive investment strategy while maintaining conservative leverage metrics.
- Market Positioning
- The extent to which IIP's focus on specialized industrial and life science real estate will differentiate it in a competitive REIT landscape.